ELECTROCORE INC (NASDAQ:ECOR) Reports Mixed Q2 2025 Earnings with Revenue Beat but Wider-Than-Expected Loss

ELECTROCORE INC (NASDAQ:ECOR) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. While revenue slightly surpassed estimates, the company’s earnings per share (EPS) fell short, contributing to a sharp negative reaction in after-hours trading.

Key Financial Highlights

• Revenue: The company posted net sales of $7.38 million, a 20% year-over-year increase from Q2 2024. This figure narrowly exceeded analyst expectations of $7.36 million. Year-to-date sales reached $14.1 million, up 22% compared to the first half of 2024.
• Earnings Per Share (EPS): Reported EPS came in at -$0.35, worse than the estimated -$0.31, reflecting ongoing operational costs and investments in commercialization efforts.
• Cash Position: As of June 30, 2025, electroCore held $7.4 million in cash, cash equivalents, restricted cash, and marketable securities.

Market Reaction

The stock tumbled ~20.6% in after-hours trading following the earnings release, signaling investor disappointment despite the revenue beat. The market’s reaction appears primarily driven by the wider-than-expected loss per share, as well as broader concerns over profitability and cash burn. Over the past month, shares have declined ~13.2%, reflecting lingering skepticism about the company’s path to sustained profitability.

Forward-Looking Estimates

Analysts project Q3 2025 revenue at $7.98 million, with an estimated EPS of -$0.26. For the full year, sales are expected to reach $31.03 million, though EPS estimates remain in negative territory at -$1.26. The company did not provide explicit guidance in its press release, leaving investors to rely on external forecasts.

Press Release Summary

The earnings announcement emphasized:

• Continued revenue growth in both quarterly and year-to-date comparisons.
• The company’s focus on expanding its non-invasive vagus nerve stimulation (nVNS) technology, including prescription device gammaCore Sapphire and consumer wellness product Truvaga.
• No significant updates on profitability milestones or cost-reduction initiatives.

For a deeper dive into electroCore’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.